View Past PerformanceBiotron バランスシートの健全性財務の健全性 基準チェック /66Biotronの総株主資本はA$2.7M 、総負債はA$0.0で、負債比率は0%となります。総資産と総負債はそれぞれA$3.9MとA$1.2Mです。主要情報0%負債資本比率AU$0負債インタレスト・カバレッジ・レシオn/a現金AU$1.64mエクイティAU$2.70m負債合計AU$1.16m総資産AU$3.86m財務の健全性に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Mar 30Biotron Limited Appoints Graeme Wald as Non-Executive Director, Effective March 30, 2026Biotron Limited announced the appointment of Graeme Wald as Non-Executive Director, effective March 30, 2026. Graeme is an Industrial Chemist and has worked as a research chemist in South Africa, Israel and the USA. He became an equities analyst and while at Merril Lynch was rated the top analyst in the Pharmaceuticals and Healthcare sector in South Africa and was a member of the top-rated Global Paper & Pulp research team. In Australia he played a leading role in growing Wilson HTM’s Life Science business to the largest in the country while Head of Lifescience research. He has extensive experience in private equity and venture capital as an Investment Director at BioScience Managers, and a Partner in Fund III at OneVentures. He has played a major role in raising more than $750M for companies in the sector and was Chairman of the Risk & Audit Committee of Nexvet Inc. while a director of the company through to its NASDAQ listing. He was also founding Chairman of Prota Therapeutics Pty Ltd. and acting CEO. He is also CEO and Director of MyrioTherapeutics Pty Ltd, a Melbourne based antibody drug company developing novel antibodies for the treatment of solid tumours and is Chairman of Psaio Therapeutics, also Melbourne based that is developing novel antibodies for the treatment of prostate cancer based on Myrio technology. He is Chairman of US based Hula Therapeutics, a private company in the clinical stage of developing a treatment for paediatric neuroblastoma, using technology partly developed by Myrio.お知らせ • Jan 30Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1.52386 million.Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1.52386 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 215,286,751 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 292,666,664 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Rights Offeringお知らせ • Dec 02Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million.Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 199,086,664 Price\Range: AUD 0.003 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 134,246,669 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Oct 15Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 199,086,876 Price\Range: AUD 0.003 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 134,246,457 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Sep 29Biotron Limited, Annual General Meeting, Nov 17, 2025Biotron Limited, Annual General Meeting, Nov 17, 2025.お知らせ • Feb 28+ 1 more updateBiotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 652,382,667 Price\Range: AUD 0.003 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 250,000,000 Price\Range: AUD 0.003 Transaction Features: Rights Offeringお知らせ • Feb 21Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 270,714,829 Price\Range: AUD 0.01お知らせ • Nov 28Biotron Limited Announces Board RetirementDr. Susan Pond and Professor Stephen Locarnini, Non-Executive Directors, have retired as Directors of Biotron Limited (Biotron) as of 28 November 2024. Dr. Pond has been a Director since 7 March 2012 and Professor Locarnini since 23 October 2018.お知らせ • Oct 22Biotron Limited, Annual General Meeting, Nov 28, 2024Biotron Limited, Annual General Meeting, Nov 28, 2024. Location: level 38 tower 3 international tower, sydney 300, barangaroo ave sydney, nsw 2000, sydney Australiaお知らせ • Oct 20Biotron Limited, Annual General Meeting, Nov 22, 2023Biotron Limited, Annual General Meeting, Nov 22, 2023, at 11:00 AUS Eastern Standard Time. Location: Level 3, 60 Carrington Street, Sydney, NSW, 2000 Sydney Australia Agenda: To receive and consider the Company's annual financial report, the directors' report and the auditors' report for the year ended 30 June 2023; to consider the That Dr. Susan M. Pond be and is hereby re-elected as a Director; to consider the That the Remuneration Report for the year ended 30 June 2023 be and is hereby adopted; to consider the Re-election of Dr. Susan M. Pond as a Director; and to consider other matters.財務状況分析短期負債: BITR.Fの 短期資産 ( A$1.7M ) が 短期負債 ( A$1.2M ) を超えています。長期負債: BITR.Fには長期負債はありません。デット・ツー・エクイティの歴史と分析負債レベル: BITR.Fは負債がありません。負債の削減: BITR.F過去 5 年間負債を抱えていません。貸借対照表キャッシュ・ランウェイ分析過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。安定したキャッシュランウェイ: BITR.Fは、前回報告された フリーキャッシュフロー に基づいて10か月分の十分な キャッシュランウェイ を有していますが、その後追加の資本を調達しました。キャッシュランウェイの予測: BITR.Fフリーキャッシュフロー 推定値 に基づいて4か月間十分なキャッシュランウェイがあると予測されていますが、その後、追加の資本を調達しました。健全な企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/21 08:23終値2026/06/15 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Biotron Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 30Biotron Limited Appoints Graeme Wald as Non-Executive Director, Effective March 30, 2026Biotron Limited announced the appointment of Graeme Wald as Non-Executive Director, effective March 30, 2026. Graeme is an Industrial Chemist and has worked as a research chemist in South Africa, Israel and the USA. He became an equities analyst and while at Merril Lynch was rated the top analyst in the Pharmaceuticals and Healthcare sector in South Africa and was a member of the top-rated Global Paper & Pulp research team. In Australia he played a leading role in growing Wilson HTM’s Life Science business to the largest in the country while Head of Lifescience research. He has extensive experience in private equity and venture capital as an Investment Director at BioScience Managers, and a Partner in Fund III at OneVentures. He has played a major role in raising more than $750M for companies in the sector and was Chairman of the Risk & Audit Committee of Nexvet Inc. while a director of the company through to its NASDAQ listing. He was also founding Chairman of Prota Therapeutics Pty Ltd. and acting CEO. He is also CEO and Director of MyrioTherapeutics Pty Ltd, a Melbourne based antibody drug company developing novel antibodies for the treatment of solid tumours and is Chairman of Psaio Therapeutics, also Melbourne based that is developing novel antibodies for the treatment of prostate cancer based on Myrio technology. He is Chairman of US based Hula Therapeutics, a private company in the clinical stage of developing a treatment for paediatric neuroblastoma, using technology partly developed by Myrio.
お知らせ • Jan 30Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1.52386 million.Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1.52386 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 215,286,751 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 292,666,664 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Rights Offering
お知らせ • Dec 02Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million.Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 199,086,664 Price\Range: AUD 0.003 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 134,246,669 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Oct 15Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 199,086,876 Price\Range: AUD 0.003 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 134,246,457 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Sep 29Biotron Limited, Annual General Meeting, Nov 17, 2025Biotron Limited, Annual General Meeting, Nov 17, 2025.
お知らせ • Feb 28+ 1 more updateBiotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 652,382,667 Price\Range: AUD 0.003 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 250,000,000 Price\Range: AUD 0.003 Transaction Features: Rights Offering
お知らせ • Feb 21Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 270,714,829 Price\Range: AUD 0.01
お知らせ • Nov 28Biotron Limited Announces Board RetirementDr. Susan Pond and Professor Stephen Locarnini, Non-Executive Directors, have retired as Directors of Biotron Limited (Biotron) as of 28 November 2024. Dr. Pond has been a Director since 7 March 2012 and Professor Locarnini since 23 October 2018.
お知らせ • Oct 22Biotron Limited, Annual General Meeting, Nov 28, 2024Biotron Limited, Annual General Meeting, Nov 28, 2024. Location: level 38 tower 3 international tower, sydney 300, barangaroo ave sydney, nsw 2000, sydney Australia
お知らせ • Oct 20Biotron Limited, Annual General Meeting, Nov 22, 2023Biotron Limited, Annual General Meeting, Nov 22, 2023, at 11:00 AUS Eastern Standard Time. Location: Level 3, 60 Carrington Street, Sydney, NSW, 2000 Sydney Australia Agenda: To receive and consider the Company's annual financial report, the directors' report and the auditors' report for the year ended 30 June 2023; to consider the That Dr. Susan M. Pond be and is hereby re-elected as a Director; to consider the That the Remuneration Report for the year ended 30 June 2023 be and is hereby adopted; to consider the Re-election of Dr. Susan M. Pond as a Director; and to consider other matters.